Aortic Stenosis clinical trials at UC Health
9 in progress, 6 open to eligible people

  • ACURATE IDE Study: Safety and Effectiveness of the Experimental Acurate Valve for Transcatheter Aortic Valve Replacement

    open to all eligible people

    To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR.

    at UC Davis

  • Aortic Valve Replacement Without Major Surgery for Patients With Aortic Stenosis (Narrowing of the Aortic Heart Valve)

    “You are being considered for this research study because you have severe aortic stenosis (narrowing of the aortic valve) without symptoms.”

    open to eligible people ages 65 years and up

    This clinical trial is a prospective, randomized, controlled, multi-center study. Patients will be randomized 1:1 to receive either transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN 3 / SAPIEN 3 Ultra THV or clinical surveillance. Patients will be stratified by whether or not they are able to perform a treadmill stress test. Patients who have a positive stress test will be followed in a registry to collect data on subsequent treatment and mortality, as applicable.

    at UC Davis

  • Fetal Intervention for Aortic Stenosis and Evolving Hypoplastic Left Heart Syndrome

    open to eligible females ages 16 years and up

    For fetuses with severe aortic stenosis, in utero balloon aortic valvuloplasty may improve fetal growth of left heart structures and thus improve potential for biventricular repair strategies after birth.

    at UCSF

  • Phono- and Electrocardiogram Assisted Detection of Valvular Disease

    open to eligible people ages 18 years and up

    The diagnosis of valvular heart disease (VHD), or its absence, invariably requires cardiac imaging. A familiar and inexpensive tool to assist in the diagnosis or exclusion of significant VHD could both expedite access to life-saving therapies and reduce the need for costly testing. The FDA-approved Eko Duo device consists of a digital stethoscope and a single-lead electrocardiogram (ECG), which wirelessly pairs with the Eko Mobile application to allow for simultaneous recording and visualization of phono- and electrocardiograms. These features uniquely situate this device to accumulate large sets of auscultatory data on patients both with and without VHD. In this study, the investigators seek to develop an automated system to identify VHD by phono- and electrocardiogram. Specifically, the investigators will attempt to develop machine learning algorithms to learn the phonocardiograms of patients with clinically important aortic stenosis (AS) or mitral regurgitation (MR), and then task the algorithms to identify subjects with clinically important VHD, as identified by a gold standard, from naïve phonocardiograms. The investigators anticipate that the study has the potential to revolutionize the diagnosis of VHD by providing a more accurate substitute to traditional auscultation.

    at UCSF

  • The PARTNER 3 - AVIV Trial

    open to eligible people ages 19 years and up

    To assess the safety and effectiveness of the SAPIEN 3 (Edwards Lifesciences, Irvine, California) transcatheter heart valve in patients with a failing aortic bioprosthetic valve.

    at UCLA

  • Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

    open to eligible people ages 18 years and up

    The objective of this study is to determine the safety and efficacy of transcatheter aortic valve replacement (TAVR) via a transfemoral approach in HF patients with moderate AS as compared with OHFT.

    at UCLA UCSD

  • Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement

    Sorry, not currently recruiting here

    The objective of this study is to evaluate the safety and effectiveness of the Lotus™ Valve System and LOTUS Edge™ Valve System for transcatheter aortic valve replacement (TAVR) in symptomatic subjects with calcific, severe native aortic stenosis who are considered at extreme or high risk for surgical valve replacement.

    at UC Davis

  • Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve

    Sorry, in progress, not accepting new patients

    The purpose of the clinical study is to prove that the heart valve device is safe, effective, and performs as intended.

    at UCLA

  • The PARTNER 3 - Trial - The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis

    Sorry, not currently recruiting here

    To establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve in patients with severe, calcific aortic stenosis who are at low operative risk for standard aortic valve replacement (AVR).

    at UCLA

Last updated: